What are the Therapeutic Implications of Met Amplification?
The presence of MET amplification can influence treatment decisions and prognostic outlook. Several MET inhibitors, such as crizotinib, capmatinib, and tepotinib, have been developed and are currently in use or under investigation for the treatment of cancers with MET amplification. These inhibitors target the MET receptor, thereby blocking the downstream signaling pathways that drive cancer growth and survival.
